Wessel, Alex W. http://orcid.org/0000-0002-0438-7842
Kose, Nurgun
Bombardi, Robin G.
Roy, Vicky http://orcid.org/0000-0002-5064-1098
Chantima, Warangkana
Mongkolsapaya, Juthathip http://orcid.org/0000-0003-3416-9480
Edeling, Melissa A.
Nelson, Christopher A.
Bosch, Irene
Alter, Galit http://orcid.org/0000-0002-7680-9215
Screaton, Gavin R. http://orcid.org/0000-0002-3549-4309
Fremont, David H. http://orcid.org/0000-0002-8544-2689
Crowe, James E. Jr http://orcid.org/0000-0002-0049-1079
Diamond, Michael S. http://orcid.org/0000-0002-8791-3165
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI073755, 75N93019C00062)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 7 April 2020
Accepted: 29 September 2020
First Online: 19 October 2020
Competing interests
: M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, Carnival CorporationĀ and on the Scientific Advisory Board of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. J.E.C. has served as a consultant for Takeda Vaccines, Sanofi-Aventis., Pfizer, and Novavax, is a member of the Scientific Advisory Boards of CompuVax and Meissa Vaccines, and isĀ the founder of IDBiologics. G.R.S. is on the Scientific Advisory Board for GSK Vaccines. G.A. is a founder of Systems Seromyx Inc. The Alter laboratory has received funding from Janssen, Merck, Sanofi, Pfizer, GlaxoSmithKline, Bristol Myers Squibb, and Gilead. All other authors declare no competing interests.